Study of CMP-CPS-001 in Healthy Volunteers
A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of CMP-CPS-001 in Healthy Volunteers
CAMP4 Therapeutics Corporation
96 participants
Feb 5, 2024
INTERVENTIONAL
Conditions
Summary
The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CMP-CPS-001 administered as a subcutaneous injection in adult healthy volunteers.
Eligibility
Inclusion Criteria3
- Healthy adults 18 to 55 years inclusive at time of informed consent
- BMI ≥18.0 and ≤32 kg/m2 at screening, and ≤110 kg
- Willing and able to sign informed consent form
Exclusion Criteria6
- Any significant disease or disorder which, in the opinion of the Investigator, may either put the study participant at risk because of participation in the study, may influence the results of the study, or may affect the study participant's ability to participate in the study
- Clinically relevant illness within 7 days before the first dose of study drug
- History of intolerance to subcutaneous injection or relevant abdominal scarring
- Laboratory results outside normal ranges at screening and judged as clinically relevant by the Investigator for liver function, kidney function, and platelets
- Positive viral serology test results for human immunodeficiency virus type 1 or 2 antibodies, hepatitis B surface antigen or hepatitis C virus antibody
- Any other safety laboratory result considered clinically significant and unacceptable by the Investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
Placebo is 0.9% normal saline solution and will be administered subcutaneously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06247670